Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Survival Analysis01:21

Cancer Survival Analysis

863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Circulating tumor DNA (ctDNA)-guided adjuvant therapy for muscle-invasive bladder cancer (MIBC): ready for primetime?

Annals of translational medicine·2026
Same author

Indirect genomic effects shape cancer risk across species.

bioRxiv : the preprint server for biology·2026
Same author

Automating neoantigen selection for personalized cancer vaccine design.

medRxiv : the preprint server for health sciences·2026
Same author

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

JCO precision oncology·2026
Same author

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.

JCO precision oncology·2026
Same author

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

Journal for immunotherapy of cancer·2026

相关实验视频

Updated: May 2, 2026

A Rapid Filter Insert-based 3D Culture System for Primary Prostate Cell Differentiation
09:23

A Rapid Filter Insert-based 3D Culture System for Primary Prostate Cell Differentiation

Published on: February 13, 2017

8.9K

国家癌症研究所生物化学复发前列腺癌工作组:临床试验设计考虑因素.

David J Einstein1, Melissa L Abel2, Jeanny B Aragon-Ching3

  • 1Beth Israel Deaconess Medical Center, Boston, MA.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
|October 23, 2025
PubMed
概括

新的指导方针针对前列腺癌 (PCa) 治疗后的生化复发 (BCR). 一个工作组定义了"PSMA+BCR",并为这种独特的疾病状态推了试验设计,重点是减强治疗以减少毒性.

更多相关视频

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.1K

相关实验视频

Last Updated: May 2, 2026

A Rapid Filter Insert-based 3D Culture System for Primary Prostate Cell Differentiation
09:23

A Rapid Filter Insert-based 3D Culture System for Primary Prostate Cell Differentiation

Published on: February 13, 2017

8.9K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.1K

科学领域:

  • 泌尿器科 泌尿器科 泌尿器科 泌尿器科
  • 在瘤学瘤学.
  • 放射学 放射学是一门学科.

背景情况:

  • 绝对治疗后前列腺癌 (PCa) 的生化复发 (BCR) 是越来越多的研究重点.
  • 目前PCa的临床试验主要针对基于传统成像的转移性疾病.
  • 现有的试验原则可能不适合未来的BCR研究.

研究的目的:

  • 建立PCa的BCR未来临床试验的原则.
  • 为解决BCR的命名,数据捕获,成像和试验设计.
  • 为了优化对超敏感成像产生的BCR的试验策略.

主要方法:

  • 一个国家癌症研究所 (NCI) 工作组 (WG) 召开讨论BCR临床试验.
  • 关键领域包括命名,基线标准,成像,高风险人群,治疗要求,生活质量和终点.
  • 讨论旨在为未来的BCR.试验开发提供信息.

主要成果:

  • 根据NCI BCR工作组的定义",前列腺特异性膜抗原 (PSMA) +BCR"用于通过PSMA PET成像检测到的PCa复发.
  • 建议使用高风险的BCR,前列腺特异性抗原的翻倍时间为≤6个月.
  • 为基线数据,成像和考虑新型终点和生活质量指标提出了建议.

结论:

  • 未来的BCR试验应为这种独特的疾病空间设计,与传统定义的转移性疾病分开.
  • 在未来的试验中,NCI BCR WG倡导降低强度的治疗策略,以尽量减少毒性.
  • 这些建议旨在改善临床试验设计和BCR中的患者结果.